Preparing to Launch Triferic, the Only FDA Approved Treatment to Deliver Iron and Maintain Hemoglobin in Hemodialysis Patients; Report Available here: www.lifescicapital.com/equity-research/rockwell
NEW YORK, NY / ACCESSWIRE / July 22, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Rockwell Medical, Inc. (NasdaqGM: RMTI), an established commercial biopharmaceutical company offering innovative products and services for hemodialysis. The Company received FDA approval on January 26th for Triferic, the only treatment indicated to replace iron and maintain hemoglobin in hemodialysis patients. Triferic has the potential to transform iron management in dialysis, and is especially well positioned in the bundled payment system. Rockwell has an established core business as a leading supplier of concentrate solutions for dialysis.
Iron deficiency is a common consequence of dialysis treatment. Delivered via dialysate, Triferic is specifically designed to replace the 5-7 mg of iron that dialysis patients lose during each session. Triferic binds to apo-transferrin upon entering the blood and is transported to the bone marrow without increasing ferritin, similar to how the body uses dietary iron. This stands in contrast to the IV iron products that are associated with severe safety problems, leaving an unmet need among dialysis patients for iron maintenance therapy. Triferic was approved in January with a strong safety profile, including no anaphylaxis in more than 100,000 administrations. Triferic is expected to create a new paradigm for managing anemia in hemodialysis patients. It has an active Q-code for reimbursement that became effective on July 1.
In a 26 page Initiation Report LifeSci Capital explains Rockwell's experience selling products into the dialysis market and how this positions Triferic and Calcitriol for commercial success. We examine the clinical data, competitive landscape, and market opportunity for the Triferic as the only FDA approved treatment to replace iron and maintain hemoglobin in hemodialysis patients.
Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Rockwell Medical as developments occur.
The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
About LifeSci Capital:
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.
Analyst Contact:
Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com
SOURCE: LifeSci Capital, LLC
